Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Another Look: Examining the market potential of DBV's Viaskin Patch and Aimmune’s AR-101 with an allergist at an academic institution

Ticker(s): AIMT, DBVT

Who's the expert?

Name: Dr Melanie Makhija - MD

Institution: Northwestern

  • Assistant Professor, Pediatrics at Northwestern; Clinical and research interests focus on food allergy including oral, sublingual and epicutaneous immunotherapy for food, eosinophilic esophagitis, asthma, and primary immunodeficiency.
  • Treats approximately 500 patients with peanut allergy & 200 patients with cow’s milk allergy (CMPA).
  • Primary and co-investigator on several multi-center national and international food allergy, immunology and asthma clinical trials.

Interview Questions
Q1.

Please describe your clinical background and how you currently manage your peanut allergy patients.

Added By: c_admin
Q2.

What % of your patients would you anticipate wanting to use AR101 if approved?

Added By: c_admin
Q3.

Can you give us your opinion as to how the safety vs benefit balance between the two drugs?

Added By: c_admin
Q4.

Is there still a need for a different treatment option or do these two potential entries to market cover most all patient cases you see?

Added By: c_admin
Q5.

How does the route of administration factor into treatment decision making?  more specifically, for the pediatric audience?  

Added By: c_admin
Q6.

I the Viaskin patch effective enough to get FDA approval?

Added By: drsug

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.